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events and patient withdrawals. Health care resource utilization
was taken from published clinical trials measuring IOP-lowering
of alternatives under evaluation and a local expert panel. Only
direct medical costs were included in the model (drug acquisi-
tion, diagnostic procedures, ophthalmologist visits and treatment
of withdrawals as second-line therapy). Drug acquisition cost
data were obtained from ofﬁcial sources while the rest of costs
data were taken from a national health care costs database. The
perspective selected for this analysis was the Spanish National
Health Service and the time horizon chosen was for three
months, the time that patients were followed-up in most of the
reported clinical trials. RESULTS: Cost per patient associated
with the use of latanoprost was of €279 while the cost per patient
secondary to use dorzolamide/timolol was of €281, with an
incremental cost of €2 per patient treated. CONCLUSIONS:
Despite Latanoprost acquisition is bigger, it is a more cost-
effective alternative than the ﬁxed-combination of dorzo-
lamide/timolol because produces similar clinical results with
lower global associated costs. Therefore, latanoprost should be
a therapeutic option to choose rather than dorzolamide/timolol
in the treatment of open-angle glaucoma in Spain.
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OBJECTIVE: Endophthalmitis is the most severe infection fol-
lowing eye trauma (injury, surgery, injection, etc.). Medical costs
and visual loss consequences are compared here. METHODS: A
mailing announcing the creation of the National Endophtalmi-
tis Survey was sent to all French ophthalmologists. A total of
424 replies were received and 346 (82%) were positive. A stan-
dardized anonymous questionnaire collected information on the
operative conditions, endophthalmitis characteristics, treatments
and clinical outcomes. The economic point of view was that of
the French NHS and medical costs were extracted from the
national Diagnosis Related Group database. Utility related to
visual acuity loss was estimated from the literature (Brown). A
€50,000/QALY threshold was used to assess cost-effective social
value related to vision loss. A 5% discount rate was used.
RESULTS: Information on 88 cases of endophthalmitis was col-
lected. The mean age was 75.1 years and 44% were women. All
patients were hospitalized, had bacteriological samples, and were
treated with either systemic or intra-vitreal antibiotics. 25.3%
had a vitrectomy. Complications were reported in 23.1% and
most were mainly retinal detachments. 3 months after surgery,
29.4% of the eyes had a visual acuity (VA) less than 1/20 and in
57.4% VA was less than 5/10. The average endophthalmitis
medical cost was €4125. The loss in utility was 0.203 on average
(baseline VA ﬁxed at 8/10). With a life expectancy of 5 years,
the average discounted social value of endophthalmitis vision
loss was €46,000. CONCLUSION: The social value attributable
to vision loss subsequent to endophthalmitis is more than ten
times higher than its medical cost.
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OBJECTIVE: To evaluate the impact of best and worst eye visual
acuity (VA) on the consumption of medical and non medical
resources in patients with wet Age-Related Macular Degenera-
tion (AMD). METHODS: This study conducted in France,
Germany and Italy was cross-sectional with some data collected
retrospectively. Patients with an exudative AMD form were
included and were stratiﬁed into four levels of severity using two
VA thresholds, 20/200 for the worst eye (WE) and 20/40 for the
best eye (BE). In addition to demographics, AMD description
and VA data, the medical and non-medical resources used for
AMD reasons during the previous year were collected. Costs
were assessed for each country according to a global payer per-
spective. An analysis of variance was performed on cost variables
to estimate the impact of each eye adjusted by sex, age and
country. RESULTS: 360 patients were included with a majority
of females (60%). Mean age at inclusion was 77 years and time
since diagnosis 2.3 years. 27% of patients had BE >20/40 and
WE >20/200 and 25.5% BE <20/40 and WE <20/200. Total costs
were €3923.5 with 64.5% of medical costs and 35.5% of non-
medical costs. Total costs increased with the AMD severity with
a cost for the more severe group 1.5 times higher than for the
less severe group. Costs were mainly associated with the BE VA.
Medical cost was higher in France (€3714 versus €1900 on
average in Germany and Italy). It increased slightly between less
severe and more severe AMD. Non medical cost was signiﬁcantly
higher for patients with more severe disease and higher in 
Germany compared to the two other countries. CONCLUSION:
This study shows the high impact of AMD on costs and the pos-
itive correlation between costs and AMD severity. Non medical
costs of the most severe patients equaled medical costs.
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OBJECTIVE: To estimate the number of patients with endoph-
talmitis hospitalized in France, its average cost and hospital
ﬁnancing consequences. METHODS: The French PMSI (Pro-
gramme de Médicalisation des Systèmes d’Information) 2003
database was analysed. Patients with the following principal
diagnoses were extracted: “purulent endophthalmitis”, “other
endophthalmitis”, and “endophthalmitis associated with
another disease”. Two mean lengths of stay (LoS) were com-
pared: the overall patient sample and the DRG-weighted esti-
mate. Endophthalmitis costs were estimated as the sum of
weighted average DRG costs plus length of stay multiplied 
by hospital variable costs. RESULTS: 1681 endophthalmitis
cases were reported (age 66.7, 50% male). 1449 cases (86.2%)
were in the public sector and 2.8% were ward transfers. A 
total of 221 (13.1%) had a vitrectomy, the most common
endophtalmitis-related surgery. A total of 85 (5.1%) required a
ward transfer and 4 (0.2%) died. The patient LoS was 7.6 days
on average while the DRG weighted LoS was 4.3 days. Thus, the
PMSI underestimates endophtalmitis LoS by 3.3 days. Mean
